Skip to main content
Journal cover image

A rationalized approach to the treatment of patients infected with hepatitis B.

Publication ,  Journal Article
Cox, NR; Patel, K; Tillmann, HL
Published in: Mol Diagn Ther
April 2014

It is estimated that there are 350-400 million individuals with chronic hepatitis B virus infection (HBV) worldwide. The natural course of HBV infection is variable with a number of individuals developing no or only mild disease, while others will die from liver-associated complications if left untreated. It is estimated that 25% of individuals with HBV infection will eventually die from the complications of HBV-associated liver disease. Several viral and host variables including hepatitis B e antigen status, HBV genotype, viral load, hepatitis B surface antigen and transaminase levels, and viral mutations have been identified as determinants of disease outcomes. The personalized approach to the treatment of chronic hepatitis B might include mere monitoring of the disease in some patients but aggressive treatment in others. Individuals who require treatment should have close monitoring to help ensure maximum medication compliance, to watch for adverse events, and to monitor virologic and biochemical responses. Therefore, management of patients with chronic HBV infection requires a practical setting to demonstrate the relevance of personalized medicine, the roles and limitations of genetic and non-genetic factors, and the risks and benefits of individualized patient care. This article provides an overview of the viral and host genetics of chronic HBV and reviews the clinical utility of serum quantitative hepatitis B surface antigen in the management of patients with chronic HBV infection.

Duke Scholars

Published In

Mol Diagn Ther

DOI

EISSN

1179-2000

Publication Date

April 2014

Volume

18

Issue

2

Start / End Page

203 / 212

Location

New Zealand

Related Subject Headings

  • Precision Medicine
  • Pharmacology & Pharmacy
  • Oncology & Carcinogenesis
  • Humans
  • Hepatitis B, Chronic
  • Hepatitis B virus
  • Hepatitis B e Antigens
  • Antiviral Agents
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cox, N. R., Patel, K., & Tillmann, H. L. (2014). A rationalized approach to the treatment of patients infected with hepatitis B. Mol Diagn Ther, 18(2), 203–212. https://doi.org/10.1007/s40291-013-0072-1
Cox, Natravis R., Keyur Patel, and Hans L. Tillmann. “A rationalized approach to the treatment of patients infected with hepatitis B.Mol Diagn Ther 18, no. 2 (April 2014): 203–12. https://doi.org/10.1007/s40291-013-0072-1.
Cox NR, Patel K, Tillmann HL. A rationalized approach to the treatment of patients infected with hepatitis B. Mol Diagn Ther. 2014 Apr;18(2):203–12.
Cox, Natravis R., et al. “A rationalized approach to the treatment of patients infected with hepatitis B.Mol Diagn Ther, vol. 18, no. 2, Apr. 2014, pp. 203–12. Pubmed, doi:10.1007/s40291-013-0072-1.
Cox NR, Patel K, Tillmann HL. A rationalized approach to the treatment of patients infected with hepatitis B. Mol Diagn Ther. 2014 Apr;18(2):203–212.
Journal cover image

Published In

Mol Diagn Ther

DOI

EISSN

1179-2000

Publication Date

April 2014

Volume

18

Issue

2

Start / End Page

203 / 212

Location

New Zealand

Related Subject Headings

  • Precision Medicine
  • Pharmacology & Pharmacy
  • Oncology & Carcinogenesis
  • Humans
  • Hepatitis B, Chronic
  • Hepatitis B virus
  • Hepatitis B e Antigens
  • Antiviral Agents
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences